Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Company Deals

Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered

Fineline Cube Jan 29, 2026
Company Deals

WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases

Fineline Cube Jan 29, 2026
Company Deals

NeuShen Therapeutics Raises Series A+ for CNS Drug Development

Fineline Cube Jan 29, 2026
Company Deals

Organon Completes $465M JADA System Sale to Laborie Medical

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Fineline Cube Jan 29, 2026
Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Fineline Cube Jan 29, 2026
Company Drug

Bayer’s Jivi Receives FDA Approval for Pediatric Hemophilia A Treatment

Fineline Cube May 20, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced this week that it has received an...

Company

Alibaba Health Reports Strong 2025 Financial Results with Revenue Hike

Fineline Cube May 20, 2025

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2025 financial report for the...

Company Drug

CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC

Fineline Cube May 20, 2025

China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its EGFR-targeted antibody-drug conjugate (ADC) CPO301...

Company Drug

Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer

Fineline Cube May 20, 2025

US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...

Company Deals

Terumo Corporation Acquires WuXi Biologics’ Germany Plant for EUR 150 Million

Fineline Cube May 19, 2025

Japan-based Terumo Corporation (TYO: 4543) has entered into an agreement with China-based Contract Research, Development...

Company

Grand Pharma’s Chengdu RDC Megafactory Secures Class A Radiation Safety License

Fineline Cube May 19, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) has obtained a Class A Radiation Safety License from...

Company Drug

Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma

Fineline Cube May 19, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...

Company Medical Device

Shanghai MicroPort’s Minos Stent Graft Secures Egyptian Marketing Approval

Fineline Cube May 19, 2025

China’s Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced that it has received...

Company Drug

Sino Biopharmaceutical’s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain

Fineline Cube May 19, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has...

Company Deals

Porton Pharma Partners with Tong Eye on iPSC-Derived RPE Cell Therapies for Ophthalmic Diseases

Fineline Cube May 19, 2025

Chinese CDMO leader Porton Pharma Solutions Ltd. has entered into a strategic partnership with domestic...

Company Drug

InnoCare Pharma Doses First Patient in Phase II/III Trial of TYK2 Inhibitor for Vitiligo

Fineline Cube May 19, 2025

Chinese biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has administered the first patient dose in...

Company Deals

Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress

Fineline Cube May 19, 2025

Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...

Company

Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down Amid Market Challenges

Fineline Cube May 19, 2025

Danish pharmaceutical giant Novo Nordisk (NYSE: NVO, CPH: NOVO-B) announced last week that Lars Fruergaard...

Others

BMS Receives EC Approval for Opdivo-based Perioperative Regimen in NSCLC

Fineline Cube May 19, 2025

Bristol-Myers Squibb (BMS; NYSE: BMY) announced last week that it has received marketing authorization from...

Company Drug

Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial

Fineline Cube May 19, 2025

US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...

Company Drug

China’s AIM Vaccine Launches Clinical Trials for mRNA Shingles Vaccine in China and US

Fineline Cube May 19, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) announced the initiation of clinical trials for its...

Company Drug

FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma

Fineline Cube May 16, 2025

The US Food and Drug Administration (FDA) announced this week an indication extension approval for...

Company Drug

Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease

Fineline Cube May 16, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...

Company Deals

Boehringer Ingelheim and Tempus Forge Multi-Year AI-Driven Oncology Drug Development Partnership

Fineline Cube May 16, 2025

Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...

Company Deals

Hainan Haiyao and Elken Global Form Five-Year Strategic Partnership in Wellness Products

Fineline Cube May 16, 2025

China-based Hainan Haiyao Co., Ltd. (SHE: 000566) has entered into a five-year strategic collaboration agreement...

Posts pagination

1 … 110 111 112 … 616

Recent updates

  • Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform
  • Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered
  • WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases
  • NeuShen Therapeutics Raises Series A+ for CNS Drug Development
  • Organon Completes $465M JADA System Sale to Laborie Medical
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Company Deals

Lisata Reclaims Certepetide China Rights Amid Kuva Acquisition, CVR Milestone Triggered

Company Deals

WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases

Company Deals

NeuShen Therapeutics Raises Series A+ for CNS Drug Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.